Equity research models and financial market analysts projecting share price targets for Lupin Limited in 2027 outline a comprehensive range based on varying market conditions. Under base-case projections, analysts anticipate the stock to trade around an average target of approximately 2,913 Indian Rupees by the end of the year, with potential mid-year peaks scaling higher depending on robust pharmaceutical portfolio performance. Bearish scenarios outline support levels closer to 2,186 Indian Rupees, while optimistic bull-market projections extend past 3,447 Indian Rupees, reflecting strong generic drug execution and international market growth.